View in EDS

Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach.

Saved in:
Bibliographic Details
Title: Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach.
Authors: Terstiege I; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.. Electronic address: Ina.Terstiege@astrazeneca.com., Aagaard A; Protein Science, Structural Biology & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Berggren K; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Bird J; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Cumming IA; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Groombridge SD; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hidestål L; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Johannesson P; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Korsgren P; Compound Synthesis and Management, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Leuchowius KJ; Assays, Profiling and Cell Sciences, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Lundqvist S; Assays, Profiling and Cell Sciences, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Scott JS; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Xue Y; Protein Science, Structural Biology & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Degorce SL; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Source: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2025 Dec 15; Vol. 131, pp. 118333. Date of Electronic Publication: 2025 Jul 28.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: England NLM ID: 9413298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3391 (Electronic) Linking ISSN: 09680896 NLM ISO Abbreviation: Bioorg Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1464-3391
DOI:10.1016/j.bmc.2025.118333